Mesoblast webcast – update on covid-19 ards trial

New york, dec. 17, 2020 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an update on the randomized controlled trial of remestemcel-l in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ards) due to covid-19 infection.

MESO Ratings Summary

MESO Quant Ranking